The ASCO presentation (May 29–June 2) is the next major catalyst — updated PFS and ORR data from the Phase 2 CRDF-004 trial could drive significant price action. The FDA alignment on Phase 3 design removes a key regulatory overhang and validates the development path. Monitor for any safety signals or efficacy updates at ASCO that could accelerate or delay the Phase 3 start.
Price Chart
Executive Summary
Cardiff Oncology reported Q1 2026 results with a net loss of $0.18 per share, slightly narrower than the $0.20 loss in Q1 2025. The key catalyst is the successful End-of-Phase 2 meeting with the FDA, aligning on the Phase 3 registrational trial design for onvansertib in first-line RAS-mutated mCRC, with updated data to be presented at ASCO in late May. Cash runway extends into Q1 2027, providing a de-risked timeline for the upcoming catalyst.
Key Financial Metrics
Key Facts
- Completed successful End-of-Phase 2 meeting with FDA; aligned on Phase 3 design for onvansertib 30mg + FOLFIRI/bev in first-line RAS-mutated mCRC
- Updated Phase 2 CRDF-004 data to be presented in rapid oral presentation at ASCO Annual Meeting (May 29–June 2)
- Q1 2026 net loss per share of $0.18 vs $0.20 in Q1 2025; net loss of $12.3M vs $13.4M year-over-year
- Cash and investments of $46.1M as of March 31, 2026, projected runway into Q1 2027
- Leadership appointments: Mani Mohindru as CEO, Josh Muntner as CFO, Ajay Aggarwal as COO
- January 2026 topline data showed 30mg onvansertib arm achieved 72.2% ORR vs 43.2% for SoC; PFS HR 0.37 (p<0.05)
Financial Impact
Q1 2026 net loss $12.3M vs $13.4M in Q1 2025; cash burn $12.3M in operating activities; cash runway into Q1 2027
Risk Factors
- Phase 3 trial execution risk and potential for regulatory delays
- Cash runway only into Q1 2027 — likely need for additional financing before Phase 3 completion
- Competitive landscape in RAS-mutated mCRC with emerging therapies
- Pre-revenue clinical-stage biotech with binary catalyst risk at ASCO
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213037-26-000013 |
| Document: crdf-20260514.htm | 0001213037-26-000013 |
| Document: 0001213037-26-000013-index-headers.html | 0001213037-26-000013 |
| Document: 0001213037-26-000013-index.html | 0001213037-26-000013 |
| Document: 0001213037-26-000013.txt | 0001213037-26-000013 |
| 8-K Data (Synthetic) | 0001213037-26-000013 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 5w ago | Institutional Cluster | $1.33 $1.17 | ▲ +12.03% | ▲ +10.84% | $0.8801 (+33.83%) |
Sep 14, 2026 6w ago | 8-K | $1.31 $1.37 | ▲ +4.58% | ▲ +4.47% | $0.8801 (−32.82%) |
Aug 11, 2026 10w ago | Press Release | $0.9900 $0.8979 | ▲ +9.30% | ▲ +8.86% | $0.8801 (+11.10%) |
Jul 16, 2026 14w ago | Insider Cluster | $0.8800 $0.8381 | ▼ −4.76% | ▼ −4.07% | $0.8801 (+0.01%) |
Jul 16, 2026 14w ago | 8-K | $0.8745 $0.8381 | ▲ +4.16% | ▲ +2.49% | $0.8801 (−0.64%) |
Jul 16, 2026 14w ago | 424B5 | $0.8745 $0.8381 | ▲ +4.16% | ▲ +2.49% | $0.8801 (−0.64%) |
Jun 22, 2026 18w ago | Insider Cluster | $1.30 $1.25 | ▼ −3.85% | ▼ −1.78% | $0.8801 (−32.30%) |
Jun 11, 2026 19w ago | Institutional Cluster | $1.59 $1.18 | ▲ +25.79% | ▲ +26.22% | $0.8801 (+44.65%) |
Jun 3, 2026 20w ago | 8-K | $1.40 $1.48 | ▲ +5.71% | ▲ +9.53% | $0.8801 (−37.14%) |
Jun 2, 2026 21w ago | Press Release | $1.51 $1.53 | ▲ +1.32% | ▲ +4.29% | $0.8801 (−41.72%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers